Bantam Pharmaceutical Announces Data on its lead drug, BTM-3566 to be Presented at the 63rd Annual Meeting of the American Society of Hematology

News 2021-11-18 | Bantam Pharma Bantam Pharmaceutical Announces Data on its lead drug, BTM-3566 to be Presented at the 63rd Annual Meeting of the American Society of Hematology November 18, 2021 Oral Presentation Will Focus on InVitro and InVivo Responses to BTM-3566 in Diffuse Large B-Cell Lymphoma RESEARCH TRIANGLE PARK, N.C. , November 18, 2021 — Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced that data on BTM-3566, in development for the treatment of hematological malignancies including Diffuse Large B-cell Lymphoma, was selected for an oral presentation at the 63 rd Annual Meeting of the American Society of Hematology (ASH), being held from December 11- 14, 2021, virtually and in-person in Atlanta. Dr. Adrian Schwarzer, MD, PhD, Hannover Medical School, will present non-clinical research on the activity and mechanism of BTM-3566 a novel, oral compound that targets mitochondrial dynamics leading to cellular stress and tumor cell apoptosis. Details of the abstract and oral presentation session are as follows: Title BTM-3566, a Novel Activator of the Mitochondrial Stress Response Promotes Robust Therapeutic Responses in Vitro and In Vivo in Diffuse Large B-Cell Lymphoma Date Monday, December 13, 2021, 4:00 P.M. ET Location Georgia World Congress Center, Room B213-B214, Level 2 Presenter Adrian Schwarzer, MD, PhD, Department of Hematology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany Abstract Available online at: https://ash.confex.com/ash/2021/wlebprogram/Paper145637.html Accepted abstracts are currently available in a special online-only issue of Blood , ASH’s official journal, at https://ashpublications.org/blood . About BTM-3566 BTM-3566 is an orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphomas (DLBCL). BTM-3566’s anti-cancer mechanism of action is unique and differentiated from other therapeutics, disrupting mitochondrial function in tumor cells to induce apoptosis (cell death). An IND application for BTM-3566 in B-cell malignancies is being completed for submission in Q1 2022. About Bantam Pharmaceutical Bantam Pharmaceutical is a drug discovery and development company channeling the power of mitochondrial dynamics to address unmet needs in oncology. Using its unique expertise in mitochondrial cellular biology, Bantam is developing novel, first-in-class small molecule oral therapeutics for difficult-to-treat hematological and solid tumors. Bantam is currently pursuing an IND application for Its lead candidate, BTM-3566, in B-cell malignancies. Learn more at https://bantampharma.com/ . Media Contact: Terri Clevenger ICR Westwicke [email protected] 203-856-4326 Company Contact: Meghan Reynolds, Chief of Staff 646.598.4823 [email protected] www.bantampharma.com

The release as fetched from its publisher. bantampharma.com ↗